RASA4: A Potential Drug Target and Biomarker (G10156)

Target Name: RASA4

NCBI ID: G10156

RASA4

RASA4: A Potential Drug Target and Biomarker

The regulation of neural circuits is critical for the proper functioning of the brain, and disruptions in this regulation have been linked to a wide range of neurological and psychiatric disorders. One of the key proteins involved in neural circuit regulation is the Retinoblastoma-associated protein (RASA4), which has been identified as a potential drug target and biomarker for a variety of neurological disorders.

RASA4 is a non-coding RNA molecule that has been shown to play a critical role in the regulation of neuronal excitability and synaptic plasticity. It is highly expressed in the brain and is involved in the development, maintenance, and regulation of neural circuits. RASA4 has been shown to play a role in the regulation of neural plasticity, including the formation of new neurons and the modulation of synaptic strength.

In addition to its role in neural circuit regulation, RASA4 has also been shown to be involved in a variety of signaling pathways that are important for brain development and function. For example, RASA4 has been shown to play a role in the regulation of microRNA (miRNA) levels, which are small non-coding RNAs that play a critical role in the regulation of gene expression. miRNA levels are regulated by a variety of factors, including RASA4, and studies have shown that RASA4 plays a critical role in the regulation of miRNA levels in the brain.

Despite its potential as a drug target, RASA4 is still an relatively unstudied protein. There are currently only a few studies that have directly addressed the role of RASA4 in neural circuit regulation, and more research is needed to fully understand its function. However, these studies have identified a number of potential targets for drug development, including inhibitors of RASA4 function that have been shown to be effective in animal models of neurological disorders.

In addition to its potential as a drug target, RASA4 may also be a valuable biomarker for a variety of neurological disorders. The regulation of neural circuits is a critical aspect of brain function, and disruptions in this regulation can be associated with a wide range of disorders. RASA4 has been shown to play a role in the regulation of neural circuit function, and studies have shown that changes in RASA4 expression levels can be associated with a variety of neurological disorders. For example, studies have shown that RASA4 levels are decreased in the brains of individuals with Alzheimer's disease, and that these changes are associated with the development of neurodegeneration in these individuals.

In conclusion, RASA4 is a protein that has been identified as a potential drug target and biomarker for a variety of neurological disorders. Its role in neural circuit regulation and its involvement in various signaling pathways make it an attractive target for drug development. Further research is needed to fully understand its function and to develop effective treatments for disorders associated with RASA4 dysfunction.

Protein Name: RAS P21 Protein Activator 4

Functions: Ca(2+)-dependent Ras GTPase-activating protein, that switches off the Ras-MAPK pathway following a stimulus that elevates intracellular calcium. Functions as an adaptor for Cdc42 and Rac1 during FcR-mediated phagocytosis

The "RASA4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RASA4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets